Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human study of FT516 to evaluate the safety and tolerability of multiple dosing cycles of FT516 in combination with FDA-approved monoclonal antibody therapy.

Trial Profile

A first-in-human study of FT516 to evaluate the safety and tolerability of multiple dosing cycles of FT516 in combination with FDA-approved monoclonal antibody therapy.

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; FT-516 (Primary) ; Pomalidomide (Primary) ; Rituximab (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Feb 2019 According to a Fate Therapeutics media release, the US FDA has allowed the IND application for the FT-516 and plans to initiate this clinical study.
    • 01 Nov 2018 According to a Fate Therapeutics media release, The Company expects to submit an IND application to the FDA by the end of 2018 for first-in-human clinical investigation of FT516 in combination with CD20 antibody rituximab and with SLAMF7 antibody elotuzumab.
    • 22 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top